FOXO4-DRI
Senolytic peptide that targets and clears senescent cells.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About FOXO4-DRI
FOXO4-DRI is a synthetic peptide designed to disrupt the FOXO4-p53 interaction that keeps senescent ('zombie') cells alive. By releasing p53, it selectively pushes senescent cells toward apoptosis while sparing healthy cells. It is an experimental longevity research compound studied for clearing accumulated senescent-cell burden.
Key Benefits
- Selectively targets senescent cells
- Disrupts the FOXO4-p53 interaction
- Studied for senescent-cell clearance
- Short, cyclical protocol
Set a goal (top of the page) to see how FOXO4-DRI scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Injection site reactions
- Fatigue
- Flu-like symptoms during clearance
Legal & Regulatory Status
Research use only. Experimental; not FDA-approved. Senolytic effects are preclinical (cell + mouse) only — no human data.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
Prices at quality-checked sources · as of July 2026 (3 weeks ago)
- $342.40
Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.
Builds a working set shared across the stack builder, calculator, scheduler and compare.